Belvedere Trading
IBRX icon

Belvedere Trading’s ImmunityBio IBRX Stock Holding History

Belvedere Trading’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-11,846
Closed -$33.5K – 975
2023
Q1 		$21.6K Sell
11,846
-8,064
-41% -$25.1K ﹤0.01% 707
2022
Q4 		$101K Buy
19,910
+2,127
+12% +$11.7K ﹤0.01% 471
2022
Q3 		$96K Sell
17,783
-166
-0.9% -$756 ﹤0.01% 193
2022
Q2 		$78K Buy
+17,949
New +$72.1K ﹤0.01% 267

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Belvedere Trading's IBRX Position: Q2 2023 in Review

Belvedere Trading sold out of ImmunityBio (IBRX) in Q2 2023, closing a stake of 11,846 shares — an estimated $33.5K sold.

Belvedere Trading first reported a position in IBRX in Q2 2022 and held it in 4 quarters. The position peaked at $101K in Q4 2022. 117 funds tracked by Wall St. Rank hold IBRX as of Q2 2023.

  • Belvedere Trading reported no remaining ImmunityBio position as of Q2 2023 after selling out during the quarter.
  • Belvedere Trading sold 11,846 ImmunityBio shares in Q2 2023, an estimated $33.5K.
  • Belvedere Trading first reported a position in ImmunityBio in Q2 2022 and held it in 4 quarters.
  • Belvedere Trading's ImmunityBio position peaked at $101K in Q4 2022.
  • 117 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2023.

Based on Belvedere Trading's 13F filing for Q2 2023, filed 8 Aug 2023.